Puma Biotechnology | PBYI - Operating Expenses


Puma Biotechnology reported $49.26M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Agios Pharmaceuticals USD 155.3M 24.53M Jun/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amgen USD 5.69B 6B Sep/2026
Biogen USD 2.32B 663.6M Sep/2026
BioMarin Pharmaceutical USD 819.04M 5.5B Sep/2026
Daiichi Sankyo JPY 483.8B 5.85B Sep/2026
Exelixis USD 390.27M 10M Sep/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
Glaxosmithkline GBP 6.76B 1.42B Sep/2026
Incyte USD 5.64B 4.67B Sep/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Moderna USD 960M 817M Jun/2026
Novartis USD 9.88B 325M Sep/2026
Pfizer USD 89B 3.81B Sep/2026
PTC Therapeutics USD 211.54M 15.12M Jun/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 33.5B 1.79B Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 390.39M 2.43M Sep/2026
Takeda JPY 981.78B 36.71B Sep/2026
TG Therapeutics USD 218.66M 48.54M Jun/2026
Ultragenyx Pharmaceutical USD 283M 6M Sep/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025
Vertex Pharmaceuticals USD 2.18B 118.2M Sep/2026